Worrywarts who thought Roche would corporatize and homogenize Genentech can rest easy. Roche is veering toward Genentech, rather than the other way around, Bloomberg reports. Even though Roche was the one that bought out Genentech in last year’s $46.8 billion deal, the Swiss drugmaker has named Genentech scientists to…
The U.S. House has moved against so-called pay-for-delay deals between branded drugmakers and generics companies. As part of a war-funding bill that passed last night, lawmakers approved new restrictions on the deals, giving the Federal Trade Commission more power to fight them.
Sanofi-Aventis is plotting a big acquisition in the U.S., sources tell Bloomberg , but there’s no word yet on the identity of the supposed target. What they do say is that the deal may be worth $20 billion or more–a price that would top what Sanofi’s spent on all…
Novartis announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).
Original Source of Phase III study shows Novartis drug Afinitor®…
Roche (SIX: RO, ROG; OTCQX: RHHBY) and IBM (NYSE: IBM) announced an agreement to develop a nanopore-based technology that will directly read and sequence human DNA quickly and efficiently.
Original Source of Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology
Olivier Bohuon, who heads
There’s at least one entity
Chalk up a victory for E.U. antitrust regulators. The General Court has ruled against AstraZeneca in an appeal, affirming the antitrust watchdog’s finding that the drugmaker abused its dominant market position when it blocked or delayed generic versions of the ulcer drug Losec. It’s been a closely watched case…
Sen. Charles Grassley (R-Iowa)
The pharmaceutical industry has eliminated 34,987 positions so far this year, second only to the goverment in total number of layoffs in 2010. That’s the bad news. The good news? Companies laid off just 830 people in June. That’s a massive plunge from May when 6,943 were eliminated ….